Silexion Therapeutics (SLXN) Price & Analysis

Compare

205 Followers

SLXN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.25 - $63.45

Previous CloseN/A

Volume52.80K

Average Volume (3M)948.69K

Market Cap

$8.20M

Enterprise Value$7.25M

Total Cash (Recent Filing)$3.47M

Total Debt (Recent Filing)$3.70M

Price to Earnings (P/E)―

Beta-0.08

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-19.98

Shares Outstanding2,123,892

10 Day Avg. Volume727,557

30 Day Avg. Volume948,694

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.88

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-249.94

Enterprise Value/Ebitda-0.40

Forecast

1Y Price Target

$24.00

Price Target Upside503.02% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentSilexion plans to initiate a Phase 2/3 study for SIL-204, with meetings scheduled with regulators to discuss and finalize the study design, indicating progress towards clinical development.

Efficacy DataSIL-204 demonstrated 97% tumor growth inhibition in a previously untested KRAS mutated line and successfully showed inhibition in both pancreatic and colorectal cancer lines.

Market PotentialKRAS mutations, which SIL-204 effectively targets, occur in high percentages of pancreatic, colorectal, non-small cell lung, and gastrointestinal cancers, indicating a broad market potential.

Bears Say

Financial ConcernsPrice target is lowered to $24 due to dilution concerns.

Share PerformanceShares are trading down ~35% following the warrant exercises.

Silexion Therapeutics News

Silexion Therapeutics announces new data in SIL204

The company states: “Silexion Therapeutics (SLXN) announced that SIL204 has demonstrated activity against eleven human cell lines originating...

11d ago

SLXN

Silexion Therapeutics files $100M mixed securities shelf

16:32 EDT Silexion Therapeutics (SLXN) files $100M mixed securities shelf Published first on TheFly – the ultimate source...

14d ago

SLXN

Silexion Therapeutics regains compliance with Nasdaq listing requirements

Silexion Therapeutics (SLXN) announced that it has received written notification from The Nasdaq Stock Market confirming that the...

16d ago

SLXN

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Investors looking for all of the latest stock market stories on Thursday will want to check out the...

30d ago

AMD

Silexion Therapeutics prices 1.5M shares at $4.00 in public offering

Silexion Therapeutics (SLXN) announced the pricing of a public offering of an aggregate of 1,500,000 of the Company’s...

30d ago

SLXN

Why Is Silexion Therapeutics Stock (SLXN) Up 190% Today?

Silexion Therapeutics stock was up on Thursday after the company posted positive pre-clinical data. ...

30d ago

SLXN

Silexion Therapeutics announces preclinical data on SIL204

Silexion Therapeutics (SLXN) announced new preclinical data demonstrating that subcutaneously administered SIL204 successfully reaches all primary sites of...

30d ago

SLXN

Buy Rating Affirmed for Silexion Therapeutics: Promising Preclinical Data and Strategic Trial Plans Boost Investment Appeal

Maxim Group analyst Naz Rahman maintained a Buy rating on Silexion Therapeutics yesterday and set a price target...

10d ago

SLXN

Silexion Therapeutics Unveils Promising SIL204 Data

An announcement from Silexion Therapeutics ( ($SLXN) ) is now available. On September 30, 2025, Silexion Therapeutics announced...

11d ago

SLXN

Silexion Therapeutics Enters Market Offering Agreement

The latest announcement is out from Silexion Therapeutics ( ($SLXN) ). On September 26, 2025, Silexion Therapeutics Corp...

14d ago

SLXN

Silexion Restores Nasdaq Compliance After Strategic Moves

Silexion Therapeutics ( ($SLXN) ) has issued an announcement. On September 23, 2025, Silexion Therapeutics Corp. received confirmation...

16d ago

SLXN

Silexion Therapeutics Converts Debt to Equity for Nasdaq Compliance

Silexion Therapeutics ( ($SLXN) ) has shared an update. On September 15, 2025, Silexion Therapeutics Corp issued 450,000...

25d ago

SLXN

Silexion Therapeutics Announces $6M Public Offering

Silexion Therapeutics ( ($SLXN) ) just unveiled an announcement. On September 11, 2025, Silexion Therapeutics announced the pricing...

28d ago

SLXN

Silexion Therapeutics Reveals Positive Preclinical Data for SIL204

Silexion Therapeutics ( ($SLXN) ) has issued an announcement. On September 11, 2025, Silexion Therapeutics announced positive preclinical...

30d ago

SLXN

SLXN FAQ

What was Silexion Therapeutics’s price range in the past 12 months?

Silexion Therapeutics lowest stock price was $3.25 and its highest was $63.45 in the past 12 months.

What is Silexion Therapeutics’s market cap?

Silexion Therapeutics’s market cap is $8.20M.

When is Silexion Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Silexion Therapeutics’s earnings last quarter?

Silexion Therapeutics released its earnings results on May 13, 2025. The company reported -$3.9 earnings per share for the quarter, missing the consensus estimate of -$3.3 by -$0.6.

Is Silexion Therapeutics overvalued?

According to Wall Street analysts Silexion Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Silexion Therapeutics pay dividends?

Silexion Therapeutics does not currently pay dividends.

What is Silexion Therapeutics’s EPS estimate?

Silexion Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Silexion Therapeutics have?

Silexion Therapeutics has 2,123,892 shares outstanding.

What happened to Silexion Therapeutics’s price movement after its last earnings report?

Silexion Therapeutics reported an EPS of -$3.9 in its last earnings report, missing expectations of -$3.3. Following the earnings report the stock price went down -4.605%.

Which hedge fund is a major shareholder of Silexion Therapeutics?

Currently, no hedge funds are holding shares in SLXN

Silexion Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-1342.57%

Trailing 12-Months

Asset Growth

-2.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Silexion Therapeutics

Silexion Therapeutics (SLXN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for rare and complex diseases. Operating within the biotechnology and pharmaceuticals sector, Silexion Therapeutics specializes in creating targeted treatments that address unmet medical needs, leveraging advanced genetic and molecular technologies to develop its core products.

Silexion Therapeutics (SLXN) Earnings & Revenues

Historic Earnings Reports

SLXN Stock 12 Month Forecast

Average Price Target

$24.00

▲(503.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","793":"$793","1580":"$1,580","399.5":"$399.5","1186.5":"$1,186.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,399.5,793,1186.5,1580],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.21,8.50153846153846,9.793076923076923,11.084615384615384,12.376153846153846,13.667692307692308,14.959230769230768,16.25076923076923,17.54230769230769,18.833846153846153,20.125384615384615,21.416923076923077,22.70846153846154,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.21,8.50153846153846,9.793076923076923,11.084615384615384,12.376153846153846,13.667692307692308,14.959230769230768,16.25076923076923,17.54230769230769,18.833846153846153,20.125384615384615,21.416923076923077,22.70846153846154,{"y":24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.21,8.50153846153846,9.793076923076923,11.084615384615384,12.376153846153846,13.667692307692308,14.959230769230768,16.25076923076923,17.54230769230769,18.833846153846153,20.125384615384615,21.416923076923077,22.70846153846154,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1528.2,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1579.5,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":197.1,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":75.09,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.67,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >